Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with a specific reporting date of April 12, 2022. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Type | Instrument | Price (GBP) | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | 17.3554 | 572 |
Note: The total volume of 572 shares represents the aggregate of 12 individual transactions executed on April 7, 2022, via the Company's Share Reward Plan.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine compliance disclosures for share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved 11 senior executives (including the CEO, Chief Commercial Officer, and Company Secretary) and one person closely associated with an executive.
- Transaction Date: All trades occurred on April 7, 2022, on the London Stock Exchange (XLON).
- Share Price: The execution price for all transactions was uniform at GBP 17.3554 per share.
- Scope: This filing does not provide data on GSK's overall financial performance for the period.